Patent News Daily Just another WordPress weblog

“To amend the public health service act to establish a pathway for the licensure of biosimilar biologic products, to promote innovation in the life sciences.” Amendment No. 297.

The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee voted Monday in favor of a proposal by Sens. Kay Hagan (D-NC), Michael Enzi (R-WY), and Orrin Hatch (R-UT) to create a follow-on biologics (FOB) pathway that provides 12 years of data exclusivity for brand-name biologic drugs.

The measure passed 16 to 7, despite an earlier decree by the Obama administration that a seven-year exclusivity limit sounded good.

The committee considered several other proposals including voting down one by Sen. Sherrod Brown (D-OH), which would have provided only 7 years of exclusivity for brand name biologics.  Sen. Edward M. Kennedy (D-MA), chairman of the HELP committee, voted by proxy to support the 12-year limit.

The vote was a small victory for major biotech drugmakers, which have been pushing for a period of 12 to 14 years before generic equivalents could be approved.  Biotech companies have been pushing for a longer period of data exclusivity saying that it can take 15 years and a $1 billion to develop and market a biotech drug so they need the longer period to make back their investment.  Generic drugmakers, not surprising, would like the exclusivity period limited to five or seven years.

This is just as small step since the Senate plan could change when the healthcare bill goes to the floor for a vote. It also must be approved by the House.

So, what will the final number be for exclusivity?  Try Follow-On Blackjack.

Related posts:

1. Economist Argues That 7 Years Ought to be Enough for Biologic Data Exclusivity As Congress is considering possible legislation to create an abbreviated...
2. Administration’s First Volley on Biosimilars: 7 Years of Exclusivity is Long Enough The Obama Administration sent out a warning shot that seven...
3. Does Congress Need A Lesson On Biotechnology or Economics? Today’s Washington Post features a story on Ismed’s efforts to...

Related posts brought to you by Yet Another Related Posts Plugin.

Posted under Biogenerics, FDA, biosimilar, biotech

Last week, on July 8, 2009, former Presidential Candidate, former Vermont Governor and former Chair of the Democratic National Committee, Howard Dean stepped into the health reform debate, discussing in an Op-ed piece published by TheHill.com. It is not surprising that Dean, who is a Medical Doctor and politician, would attempt to let [...] Related posts:

1. Obama Administration Wants Short Biologic ExclusivityUntil recently the Obama Administration had not taken any particularly strong or controversial stanc
2. US Manufacturers Tell Obama Patent Reform Will Cost US JobsEarlier today more than 130 US manufacturing companies sent a joint letter to President Obama detail
3. Green Tech Companies Protest Patent Reform LegislationIn a new, interesting and exciting twist, green technology companies are joining the debate about wh

Related posts brought to you by Yet Another Related Posts Plugin.

Posted under Biotechnology, IP News, IPWatchdog.com Blog, Patent Fools™, Patent Reform, Pharma, Technology & Innovation, biosimilars, biotech, follow on biologics, howard dean, obama, patent